Conclusion
Most of the current trends in the management of asthma are devoted to environmental and pharmacological interventions. The major drawbacks of the so-called controversial therapies remain the lack of convincing proof of efficacy and safety. They are certainly not to be advocated as a first-line treatment for asthma. The physicians need to know them better to demonstrate to the patient their inaccuracies and their potential side effects. The goal of the modern treatment of asthma is to educate the patient to develop a good and confident partnership. Based on that partnership, the patient might talk without fear about these nonvalidated methods of treatment. Psychological intervention is an integrated part of asthma management, and physical training might be of great help to improve the quality of life of our patients. More rigorous studies are warranted to establish the validity of these controversial treatments. It is important to advise patients strongly not to stop their current treatment if these alternative forms of treatment are used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Heart, Lung, and Blood Institute. National Asthma Education Program (1991),J. Allergy Clin. Immunol. 88, 425–534.
Lane, D. J. and Lane, T. V. (1991),Thorax 46, 787–797.
Fung, K.P., Chow, O. K., and So, S. Y. (1986),Lancet 2, 1419–1422.
Tashkin, D. P., Kroening, R. J., Bresler, D. E., Simmons, M., Coulson, A. H., and Kerschnar, H. A. (1985),J. Allergy Clin. Immunol. 76, 855–864.
Tandon, M. K. and Soh, P. F. (1989),Chest 96, 102–105.
Kleijnen, J. T. R. and Knipschild, P. (1991),Thorax 46, 799–802.
Wright, R. S., Kupperman, J. L., and Liebhaber, M. I. (1991),West. J. Med. 154, 102,103.
Morice, A. (1986),Lancet 1, 862,863.
Ewer, T. C. and Stewart, D. E. (1986),Br. Med. J. Clin. Res. Ed. 293, 1129–1132.
Nagarathna, R. and Nagendra, H. R. (1985),Br. Med. J. Clin. Res. 291, 1077–1079.
Singh, V., Wisniewski, A., Britton, J., and Tattersfield, A. (1990),Lancet 335, 1381–1383.
Nagendra, H. R. and Nagarathna, R. (1986),J. Asthma 23, 123–137.
Wagner, H., Dorsch, W., Bayer, T., Breu, W., and Willer, F. (1990),Prostaglandins Leukotrienes Essential Fatty Acids 39, 59–62.
Nakamura, T., Kuriyama, M., Kosuge, E., Ishihara, K., and Ito, K. (1993),Ann. NY Acad. Sci. 685, 572–579.
Egashira, Y. and Nagano, H. (1993),Ann. NY Acad. Sci. 685, 580–583.
Nogrady, S. G. and Furnass, S. B. (1983),Thorax 38, 919–922.
Executive Committee of the American Academy of Allergy and Immunology (1986),J. Allergy Clin. Immunol. 78, 273–275.
Honda, Y., Hashizume, I., Kimura, H., and Severinghuas, J. W. (1988),Jpn. J. Physiol. 38, 917–928.
Arm, J. P., Horton, C. E., Mencia-Huerta, J. M., House, F., Eiser, N. M., Clark, T. J., Spur, E. W., and Lee, T. H. (1988),Thorax 43, 84–92.
Arm, J. P., Horton, C. E., Spur, E. W., Mencia-Huerta, J. M., and Lee, T. H. (1989),Am. Rev. Respir. Dis. 139, 1395–1400.
Lee, T. H., Arm, J. P., Horton, C. E., Crea, A. E., Mencia-Huerta, J. M., and Spur, E. W. (1991),Allergy Proc. 12, 299–303.
Thien, F. C., Mencia-Huerta, J. M., and Lee, T. H. (1993),Am. Rev. Respir. Dis. 147, 1138–1143.
Hasselmark, L., Malmgren, R., Unge, G., and Zetterstrom O. (1990),Allergy 45, 523–527.
Hasselmark, L., Malmgren, R., Zetterstrom, O., and Unge, G. (1993),Allergy 48 30–36.
Varray, A. L., Mercier, J. G., Terral, C. M., and Prefaut, C. G. (1991),Chest 99, 579–586.
Bundgaard, A., Ingemann-Hansen, T., Halkjaer-Kristensen, J., Schmidt, A., Block, I., and Andersen, P. K. (1983),Br. J. Dis. Chest 77, 147–152.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chanez, P., Bousquet, J., Godard, P. et al. Controversial forms of treatment of asthma. Clinic Rev Allerg Immunol 14, 247–252 (1996). https://doi.org/10.1007/BF02802217
Issue Date:
DOI: https://doi.org/10.1007/BF02802217